DURECT Corporation announced top-line results from its phase IIa clinical trial of DUR-928 for mild to moderate plaque psoriasis. While the drug was well tolerated, it did not demonstrate a meaningful benefit over placebo in the trial, and DURECT will no longer be pursuing this indication, instead focusing on trials of DUR-928 for nonalcoloholic steatohepatitis (NASH). Will our extensive experience with clinical trials, Yourway knows the importance of agile decision making to determine which trials to terminate and which to pursue.